Facts are management is seeking collaborator for HBV more soundly now comparing with last year when the latest test results were reported. One reason perhaps is that currently the company portfolio is left with two programmes only.
Jerel clearly revealed (during the questions time) just a few weeks ago at Ladenburg Thalmann Conference that potential partners for HBV are doing their due diligence before eventually anyone steps in for any kind of partnership.
But everyone is aware of the delivery issues this technology has and because of this it seems naive to expect such kind of collaboration to eventuate any soon, especially after the failed case with Axovant. Now even further studies are underway with OPMD.
The question is could there be a reason of which the shareholders are not aware of, which makes Jerel and the rest optimistic for HBV partnership?
Thank you.
BLT Price at posting:
4.6¢ Sentiment: Hold Disclosure: Held
